Login / Signup

A library-derived peptide inhibitor of the BZLF1 transcription factor.

Sarah K MaddenAndrew BrennanJody M Mason
Published in: Journal of peptide science : an official publication of the European Peptide Society (2023)
Transcription factor dysregulation is associated with many diseases, including cancer. Peptide-based molecules are increasingly recognised as important modulators of difficult intracellular protein-protein interaction targets, with peptide library screening consequently proven to be a viable strategy in developing inhibitors against a wide range of transcription factors (TFs). However, current strategies simply select the highest affinity of binding to a target TF rather than the ability to inhibit TF function. Here, we utilise our Transcription Block Survival (TBS) screening platform to enable high-throughput identification of peptides that inhibit TFs from binding to cognate DNA sites, hence inhibiting functionality. In this study, we explore whether the TBS can be expanded to derive a potent and functional peptide inhibitor of the BZLF1 transcription factor. The library-derived peptide, AcidicW, is shown to form a more stable dimer with BZLF1 than the BZLF1 homodimer, with a thermal denaturation temperature exceeding 80°C. AcidicW can also functionally inhibit the BZLF1:TRE DNA interaction with high potency and an IC 50 of 612 nM.
Keyphrases
  • transcription factor
  • high throughput
  • dna binding
  • protein protein
  • cell free
  • circulating tumor
  • single molecule
  • squamous cell carcinoma
  • young adults
  • single cell
  • squamous cell
  • childhood cancer